Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma(PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas

Trial Profile

Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma(PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications B cell lymphoma; Cutaneous B-cell lymphoma; Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2017 Planned initiation date changed from 13 Oct 2017 to 18 Oct 2017.
    • 07 Oct 2017 Planned initiation date changed from 3 Oct 2017 to 13 Oct 2017.
    • 28 Sep 2017 Planned initiation date changed from 29 Sep 2017 to 3 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top